Melanoma Clinical Trial

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Summary

RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer.

PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.

View Full Description

Full Description

OBJECTIVES:

Correlate degree of melastatin gene expression with risk of developing local regional metastases in patients with primary stage I or II melanoma.
Correlate melastatin expression prospectively with event-free survival of these patients.

OUTLINE: This is a multicenter study.

Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.

Patients are followed every 4 months for 3.5 years.

PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study within 3.5 years.

View Eligibility Criteria

Eligibility Criteria

Histologically documented primary AJCC stage I or II melanoma. Evidence of ulceration, vertical growth phase, regression, lymphocytic infiltration, vascular invasion, microscopic satellitosis, and mitotic rate shall be noted.
Patients planning to undergo a sentinel lymph node biopsy, or an elective lymph node dissection of an anatomic draining region from the index primary melanoma.
≥18 years of age
Patients must be registered prior to planned surgery. The surgery must be performed within 45 days following registration.
No concurrent active malignancy other than carcinoma in situ of the cervix and basal cell carcinoma of the skin, or history of any other primary malignancy including previously primary melanoma.
Tissue blocks: one of primary tumor tissue taken from region of greatest Breslow thickness. Note: If blocks cannot be sent due to institutional policy, slides may be substituted for the locks per the protocol.

Study is for people with:

Melanoma

Estimated Enrollment:

314

Study ID:

NCT00049010

Recruitment Status:

Completed

Sponsor:

Alliance for Clinical Trials in Oncology

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 24 Locations for this study

See Locations Near You

University of Chicago Cancer Research Center
Chicago Illinois, 60637, United States
Iowa Blood and Cancer Care
Cedar Rapids Iowa, 52402, United States
St. Luke's Hospital
Cedar Rapids Iowa, 52402, United States
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids Iowa, 52403, United States
Massachusetts General Hospital Cancer Center
Boston Massachusetts, 02114, United States
Brigham and Women's Hospital
Boston Massachusetts, 02115, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston Massachusetts, 02115, United States
Commonwealth Hematology-Oncology P.C. - Worcester
Worcester Massachusetts, 01605, United States
Fairview University Medical Center - University Campus
Minneapolis Minnesota, 55455, United States
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia Missouri, 65203, United States
Capital Region Cancer Center
Jefferson City Missouri, 65101, United States
Kingsbury Center for Cancer Care at Cheshire Medical Center
Keene New Hampshire, 03431, United States
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls New York, 12801, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10021, United States
CCOP - Hematology-Oncology Associates of Central New York
Syracuse New York, 13057, United States
Community General Hospital of Greater Syracuse
Syracuse New York, 13215, United States
Wayne Memorial Hospital, Incorporated
Goldsboro North Carolina, 27534, United States
Wayne Radiation Oncology
Goldsboro North Carolina, 27534, United States
Wilson Medical Center
Wilson North Carolina, 27893, United States
Wake Forest University Comprehensive Cancer Center
Winston-Salem North Carolina, 27157, United States
Rhode Island Hospital
Providence Rhode Island, 02903, United States
Miriam Hospital at Lifespan
Providence Rhode Island, 02906, United States
Roper St. Francis Cancer Center at Roper Hospital
Charleston South Carolina, 29401, United States
Mountainview Medical
Berlin Vermont, 05602, United States
Fletcher Allen Health Care - University Health Center Campus
Burlington Vermont, 05401, United States
Danville Regional Medical Center
Danville Virginia, 24541, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

314

Study ID:

NCT00049010

Recruitment Status:

Completed

Sponsor:


Alliance for Clinical Trials in Oncology

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider